28
Nov

Synpromics collaborates with UCL to generate a range of synthetic gene promoters for the CNS to develop a gene therapy for Parkinson’s disease.

06
Oct
Synpromics OBN Awards

Synpromics have been awarded Best Emerging UK Synthetic Biotech Company at the 2017 OBN Awards for enabling safer, more effective cell and gene medicines.

20
Sep

Synpromics will provide key muscle-selective promoter candidates for the development of new treatment options for Duchenne muscular dystrophy (DMD).

11
Sep
Roslin Innovation Centre

The new custom-built centre based at the University of Edinburgh’s allows us to meet increasing global demand for its cutting-edge gene control technology.

19
Apr

Synpromics, the leading synthetic promoter and gene control company, is pleased to announce that it has completed a financing round of £5.2M.

Pages